Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors

Rationale: The aim of this study is to investigate if following the implementation of the Regulation EU/1235/2010 and the Directive 2010/84/EU there was an increase of individual case safety reports (ICSRs) deriving from a medication error, abuse, misuse, overdose, or occupational exposure. Other objectives are the identification of drugs mostly involved in such cases, to establish if the codification of aforementioned conditions is performed correctly and, whenever codification errors exist, to identify predictors of codification errors. Finally, we estimated the magnitude of these errors on signal detection activities. Methods: ICSRs sent through Campania Region (Italy) spontaneous reporting system from July 2nd 2012 to December 31th 2017 were used as data source. A multivariable logistic regression model was used to identify predictors of codification errors. Four measures of disproportionality were used to investigate the magnitude of codification errors on a known safety signal or rather the association between benzodiazepines derivatives and abuse. Results: In all, 358 (1.4%) out of 25610 ICSRs reported “non-normal use” of drugs, mainly as cases of abuse. Drugs mostly involved in abuse were “Benzodiazepines derivatives” (171/358; 47.8%). For medication errors instead, “Other antiseptics and disinfectants” (9/358; 2.5%). At the first quality control, 125 (34.9%) out of 358 ICSRs did not have a codification of “non-normal use” or codifications were performed wrongly. Codification errors included misclassification of abuse as overdose (10/125; 8.0%) and misclassification of medication error as overdose (7/125; 5.6%) or abuse (7/125; 5.6%). Compared to pharmaceutical companies, patients/citizens (as reporters) had a 24.88 higher odd (Reporting Odds Ratio 24.88, 95%CI 1.82–449.95; p-value: 0.02) of performing un-classification or misclassification of aforementioned codifications. Codification errors were associated with the underestimation of measure of disproportionality' estimates in the identification of the safety signal “Benzodiazepine derivatives /abuse”. Conclusion: In conclusion, this study found that in Campania Region (southern Italy) there was an exponential increase of ICSR reporting “non-normal use,” mainly as cases of abuse, with an improvable proportion of cases misclassified/unclassified. Moreover, this study found that ICSRs sent by patients/citizens were associated with an increased odd of un-classification or misclassification that had a relevant impact on signal detection activities.

[1]  C. Scavone Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system , 2018 .

[2]  E. Clementi,et al.  The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions , 2017, The Pharmacogenomics Journal.

[3]  C. Scavone,et al.  Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions , 2017, Front. Pharmacol..

[4]  E. Russo,et al.  Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation , 2017, Expert opinion on drug safety.

[5]  K. Taxis,et al.  The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis , 2017, Drug Safety.

[6]  L. Berrino,et al.  Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs , 2016, Expert opinion on drug safety.

[7]  A. Rotondo,et al.  Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions , 2016, Expert opinion on drug safety.

[8]  C. Torp-Pedersen,et al.  Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study , 2016, PloS one.

[9]  Ruwen Böhm,et al.  OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications , 2016, PloS one.

[10]  M. Sessa,et al.  A case of figurate urticaria by etanercept , 2016, Journal of pharmacology & pharmacotherapeutics.

[11]  M. Sessa,et al.  Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases , 2016, Drug Safety.

[12]  F. Manguso,et al.  Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. , 2016, Pharmacological research.

[13]  M. Sessa,et al.  Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy , 2014, Expert opinion on drug safety.

[14]  V. Bauchau,et al.  The upper bound to the Relative Reporting Ratio—a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection , 2014, Pharmacoepidemiology and drug safety.

[15]  G. Perna,et al.  Unusual case of severe arrhythmia developed after acute intoxication with tosylchloramide , 2013, BMC Pharmacology and Toxicology.

[16]  Chun-Mei Zhao,et al.  Complexity of gastric acid secretion revealed by targeted gene disruption in mice. , 2010, Current pharmaceutical design.

[17]  D. Spyker,et al.  2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report , 2008, Clinical toxicology.

[18]  E. Sellers,et al.  Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations , 2007, The Clinical journal of pain.

[19]  G. Neale,et al.  Self-harm and suicide associated with benzodiazepine usage. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.

[20]  Richard C Dart,et al.  The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). , 2007, Pain medicine.

[21]  C. O'brien Benzodiazepine use, abuse, and dependence. , 2005, The Journal of clinical psychiatry.

[22]  Kenneth J Rothman,et al.  The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.

[23]  Lehana Thabane,et al.  Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.

[24]  L P Longo,et al.  Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. , 2000, American family physician.

[25]  R. Rinaldi,et al.  Clarification and standardization of substance abuse terminology. , 1988, JAMA.

[26]  Canary Wharf,et al.  Guidelines on good pharmacovigilance practices (GVP) , 2012 .

[27]  WHO launches Pharmacovigilance Toolkit , 2012, Reactions Weekly.

[28]  M. Rawlins Pathogenesis of adverse drug reactions , 1977 .